Literature DB >> 23160536

uPAR signaling is under par for the podocyte course.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160536     DOI: 10.1007/s00109-012-0980-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  9 in total

1.  Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.

Authors:  Bin Zhang; Shaoting Xie; Wei Shi; Yun Yang
Journal:  Nephrol Dial Transplant       Date:  2011-11-09       Impact factor: 5.992

2.  Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.

Authors:  Yulia Kiyan; Anne Limbourg; Roman Kiyan; Sergey Tkachuk; Florian P Limbourg; Aleksandr Ovsianikov; Boris N Chichkov; Hermann Haller; Inna Dumler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-10       Impact factor: 8.311

Review 3.  The urokinase system in the pathogenesis of atherosclerosis.

Authors:  Bianca Fuhrman
Journal:  Atherosclerosis       Date:  2011-11-16       Impact factor: 5.162

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

5.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Authors:  Changli Wei; Shafic El Hindi; Jing Li; Alessia Fornoni; Nelson Goes; Junichiro Sageshima; Dony Maiguel; S Ananth Karumanchi; Hui-Kim Yap; Moin Saleem; Qingyin Zhang; Boris Nikolic; Abanti Chaudhuri; Pirouz Daftarian; Eduardo Salido; Armando Torres; Moro Salifu; Minnie M Sarwal; Franz Schaefer; Christian Morath; Vedat Schwenger; Martin Zeier; Vineet Gupta; David Roth; Maria Pia Rastaldi; George Burke; Phillip Ruiz; Jochen Reiser
Journal:  Nat Med       Date:  2011-07-31       Impact factor: 53.440

6.  The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.

Authors:  Bin Zhang; Wei Shi; Juan Ma; Alexis Sloan; Christian Faul; Changli Wei; Jochen Reiser; Yun Yang; Shuangxin Liu; Wenjian Wang
Journal:  J Mol Med (Berl)       Date:  2012-09-27       Impact factor: 4.599

Review 7.  Urokinase plasminogen activator system as a potential target for cancer therapy.

Authors:  Ahmed H Mekkawy; David L Morris; Mohammad H Pourgholami
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 8.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

9.  Modification of kidney barrier function by the urokinase receptor.

Authors:  Changli Wei; Clemens C Möller; Mehmet M Altintas; Jing Li; Karin Schwarz; Serena Zacchigna; Liang Xie; Anna Henger; Holger Schmid; Maria P Rastaldi; Peter Cowan; Matthias Kretzler; Roberto Parrilla; Moïse Bendayan; Vineet Gupta; Boris Nikolic; Raghu Kalluri; Peter Carmeliet; Peter Mundel; Jochen Reiser
Journal:  Nat Med       Date:  2007-12-16       Impact factor: 53.440

  9 in total
  3 in total

Review 1.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

2.  1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.

Authors:  Jianchao Ma; Bin Zhang; Shuangxin Liu; Shaoting Xie; Yun Yang; Juan Ma; Yujun Deng; Wenjian Wang; Lixia Xu; Ruizhao Li; Li Zhang; Chunping Yu; Wei Shi
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

3.  Urokinase-type plasminogen activator receptor in IgA nephropathy.

Authors:  Shin-Young Ahn; Ho Jun Chin
Journal:  Korean J Intern Med       Date:  2014-02-27       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.